Visit Nektar Therapeutics

We look forward to @AAPSComms #PharmSci360 on October 17-20. Check out this on-demand session on our IL-2 #immunotherapy BEMPEG (NKTR-214) led by Nektar’s Executive Medical Director, David Chien, M.D.: https://t.co/4ZkrqyE1sZ #cancer https://t.co/9VBbVFddsI

Thank you to Jaqui, our @CALifeSciences @NexGeneGirls summer intern, for recapping your experiences and passion for #STEM. Please check out her new blog post! https://t.co/4FeD3Xm8Ar

Wildaliz Nieves, Ph.D., a scientist at Nektar, mentored a @NexGeneGirls mentee this summer. Read our Q&A on inspiring the next generation of #STEM leaders and why we are proud to support our local communities: https://t.co/kEESz41cUu #NexGeneGirls #GirlsinSTEM #WeCommitToChange

The 2021 @CancerResearch Virtual #Immunotherapy Patient Summit is on October 7-8. It’s an exciting opportunity to engage with experts, learn about scientific advances and connect with the #cancer community. Register here for free: https://t.co/QrrEcbo2vi

IL-15-based #immunotherapies have shown promise in treatment of #cancer. Read about how Nektar is harnessing the full spectrum of IL-15 biology to develop therapies for a variety of tumor types in a new @statnews sponsored article: https://t.co/RNqn6OFrNJ

Dedicated to scientific innovation, Nektar is proud to be researching our IL-15 agonist in clinical trials of patients with blood #cancer and solid #tumors. Learn more about the promising potential of the IL-15 pathway: https://t.co/Tm25gix1QS https://t.co/KZ1GmWXtta

It’s time to #cancelbloodcancer. We are proud to be evaluating the potential of IL-15 agonist NKTR-255 in combination with rituximab and daratumumab for patients with #multiplemyeloma and #nonHodgkinlymphoma. Learn more: https://t.co/zPoCrgKvWo #BloodCancerAwarenessMonth https://t.co/6lqpwyyumV

Thank you to #ESMO2021 for a great meeting and to our authors for presenting on our clinical studies of BEMPEG, our novel IL-2 agonist, and NKTR-255, our IL-15 agonist. Explore the posters: https://t.co/fgiLXXq5IZ #cancer #oncology #immunooncology https://t.co/PmKYEMv6We

Our new clinical collaboration with @EMDOncologyUS and Pfizer exemplifies our dedication to #immunooncology innovation. NKTR-255 will be combined with avelumab in the new JAVELIN Bladder Medley study for evaluation in #urothelialcarcinoma. Learn more: https://t.co/OSKB5DCPCf https://t.co/rYuGnn8OXI

Join us at the Next-Gen #Cytokine Therapeutics Summit on 9/22, where our VP of #Oncology Research Willem Overwijk will be delivering opening remarks and a keynote presentation on NKTR-255, our IL-15 #immunotherapy, and moderating a panel. Register here: https://t.co/gSXXE2e2Pq https://t.co/vHTy1CUteB

At #ESMO2021, Dr. Siefker-Radtke presented exciting translational assay concordance data from PIVOT-10, a Phase 2 study in metastatic urothelial cancer of BEMPEG plus NIVO, for which clinical data are expected next year. Explore the poster: https://t.co/fgiLXXHH7z #immunooncology https://t.co/lyHc5b1qij

We’re looking forward to presenting PIVOT-10 concordance data and sharing our NKTR-255 solid tumor trial in progress at #ESMO2021. #cancer #oncology #immunooncology https://t.co/7DpXzeb7uS

We are proud to support @sitcancer and the next generation of #cancer #immunotherapy researchers. Congratulations to Dr. Elen Torres, recipient of the SITC-Nektar Therapeutics Equity and Inclusion in Immunotherapy award. Learn more: https://t.co/DZOY1PXPOG https://t.co/p4a3owf9Zs

We are pleased to welcome Dr. Dimitry S.A. Nuyten as our SVP, Chief Medical Officer. He brings extensive experience establishing and executing clinical strategy for #oncology and #immuno-oncology programs across all stages of development. Read more: https://t.co/PwHI07mMIH https://t.co/1BiIjNQ1Gf

Thank you to @STEMSaturdaysf for hosting a fantastic event this past weekend celebrating #STEM with diverse young members of our community and their families! Learn more about #stemsaturdaysf: https://t.co/BFAmcGXYWk https://t.co/ZwT0W7Ksh8

We are excited to be part of the first @STEMSaturdaysf festival to inspire the next generation of #STEM leaders. Join us tomorrow in exploring polymer science via balloon skewer experiments and slime making. https://t.co/BFAmcGXYWk #stemsaturdaysf https://t.co/XHlvCfCY5E

We are excited that John Hayslip, M.D., joined as VP of Clinical Development. He has 15+ years of experience overseeing clinical trials in biopharma and academic settings and will be instrumental as we advance our pipeline. Learn more: https://t.co/5pOgS2s3av #drugdevelopment https://t.co/JaQcskaoCN

Our Ph II study of BEMPEG plus NIVO is featured in @ASCO_Pubs Journal of Clinical Oncology. This #JCO publication highlights encouraging safety and efficacy data in patients with first-line metastatic #melanoma. View here: https://t.co/6syhdYVfJ2 #immunotherapy https://t.co/XbfbPiEKMP

Nektar honors patients and families this #CIM21 and throughout the year as we leverage the power of immunotherapy to improve treatment for a broad range of solid tumors and blood cancers. Learn more about our R&D programs: https://t.co/zPoCrgKvWo #immune2cancer https://t.co/M7KWZ9ODmJ

At Nektar, we’re leveraging pathways that activate the immune system to fight #cancer. To learn more about our cancer programs targeting the IL-2, IL-15 and TLR 7/8 pathways, visit: https://t.co/O9gxFxdSiw #CIM21 https://t.co/E8vf2pUJRj